Texas

“The future will be overrun by an army of new choices and changes in attitudes towards one’s own health. That creates a whole new area for bioscience and health, and for investing,” Mike Edelhart, managing partner, Social Starts & Joyance Partners said.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.

It was an unusually busy week for clinical trial updates, largely because of the annual ASH meeting from Sunday December 5 through Wednesday December 9. There were also other meetings and the usual corporate updates.

Palbociclib is the standard of care for patients with advanced breast cancer, yet researchers still have no molecular profile to predict which patients will progress, which will continue benefitting from this therapy after their initial treatment, and which combination therapies are most effective.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

With the expected Emergency Use Authorization (EUA) of Pfizer-BioNTech and Moderna’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience?

The 2020 Virtual Texas Life Science Forum, sponsored by BioHouston November 10-12, showcased dozens of innovative, early stage companies seeking partners to reach the next level.

The COVID-19 pandemic changed the biopharma industry and the world irrevocably. The challenges will reverberate even after the pandemic ends, according to panelists at the Cell and Gene Meeting on the Mesa in mid-October.

Thursday afternoon, Bellicum announced it will pause the development of its BCMA GoCAR-NK program and will also discontinue discovery research and new product development.